NCT07657988RecruitingNot Applicable
Patient and Clinician Reported Outcomes Among Patients With Actinic Keratosis Receiving Tirbanibulin for Large fiEld Application on the Face, in U.S Clinical pRactice Settings: A Pilot Initiative (CLEAR)
Avant Health LLC2 sites in 1 country30 target enrollmentStarted: April 2, 2026Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 30
- Locations
- 2
Study Overview
Brief Summary
The goal of this observational study is to learn about the effectiveness of tirbanibulin among adult subjects with actinic keratosis (AK) lesions in the face. The main question it aim to answer is:
How does tirbanibulin improve subject's overall appearance of the skin, improve how patient's skin looks, and improve patient's skin texture, in a 57-day observation period.
Participants already taking tirbanibulin as part of their regular medical care for AK will answer online survey questions at the beginning of the study and at Day 57.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Diagnosed with AK on the face.
- •Has clinically typical, visible, and discrete 4-12 AK lesions on the face.
- •Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face.
- •Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin.
- •Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration.
- •Able to read and write in English.
- •Provide consent to participate in the study.
- •Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study.
Exclusion Criteria
- •Patients with any dermatological condition of the face that could interfere with clinical evaluations.
- •Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area.
- •Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
- •Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study.
- •Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
Exploratory study to determine the tolerability and effectiveness of Tirbanibulin in the treatment of Actinic Cheilitis - Cheilitis trial2022-502807-31-00Technische Universitat Dresden20
Recruiting
Not Applicable
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After LorlatinibNon-Small Cell Lung CancerNCT07374614Peking University Shenzhen Hospital20
Not yet recruiting
Phase 3
A study to examine usefulness and safety of remibrutinib in patients with generalized myasthenia gravis.CTRI/2025/07/092102Novartis Healthcare Pvt Ltd180
Recruiting
Phase 2
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell CarcinomaNCT07290010Hebei Medical University Fourth Hospital25
Not yet recruiting
Not Applicable
A Real-World Study of Pirtobrutinib in cBTKi-Resistant/Intolerant Mature B-Cell LymphomaMature B-Cell LymphomaNCT07525817Ou Bai, MD/PHD40